Aisha Baqai

Aisha Baqai practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Aisha Baqai's NPI, 1003054966, was assigned on January 30, 2009. Aisha Baqai graduated from Weill Cornell Medicine in 2007. Aisha Baqai holds Connecticut license 050860.

Aisha Baqai's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Aisha Baqai's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Aisha Baqai is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Aisha Baqai to 2 more medical groups, each named with a free account. Aisha Baqai's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Aisha Baqai practices, 2 sites in all. Vendor and product names are available with a free account.

Anesthesiology is Aisha Baqai's primary specialty in the NPI Registry, under taxonomy code 207L00000X. Aisha Baqai is board certified in anesthesiology by the American Board of Anesthesiology. Aisha Baqai is licensed in Connecticut.

CMS data shows 638 Medicare services from Aisha Baqai across 11 procedure codes in 2024, for 348 Medicare patients. Medicare paid $52,463 for them.

CMS counts 348 Medicare patients who saw Aisha Baqai in 2024. The largest group is 65 to 74, with 173 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Aisha Baqai's median patient age at 69, with 59% women.

In 2024, Aisha Baqai wrote 1,697 Medicare Part D claims for 158 patients. 91% of them were for generic drugs. CMS names the drug for 1,664 of them, across 24 drugs with 11 or more claims each, at $158,482 in total drug cost. In 2023, CMS named 1,767 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Aisha Baqai for performance year 2024, reported as part of a group. Aisha Baqai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Aisha Baqai as offering telehealth.

Dmand AI links 2 papers to Aisha Baqai, published from 2012 to 2016. Aisha Baqai's most frequent co-authors are Amitabh Gulati, MD, Jatin H. Joshi, MD and Neel D. Mehta, MD.

Dmand AI links Aisha Baqai to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 3 general payments to Aisha Baqai from 2 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $144.

Aisha Baqai graduated from Weill Cornell Medicine in 2007.